1) Dozens of drug makers agree on effort to combat antibiotic resistance – STAT, 1/20/2016
In an unprecedented bid to address antibiotic resistance, more than 80 drug and device makers have issued a declaration urging governments to “support investment” in developing medicines and diagnostic tools to combat drug-resistant infections.
2) Exclusive: Fast-growing gene-editing biotech expanding near Kendall Square – BBJ, 1/22/2016
A rapidly growing Cambridge-based gene-editing company has snapped up 65,000 square feet of coveted East Cambridge real estate with plans to house a newly created division in the space.
3) GE Life Sciences to hire 100 more people in 2016 – BBJ, 1/21/2016
As General Electric Co. prepares to move to relocate corporate headquarters to Massachusetts, GE Healthcare Life Sciences is finalizing its own move into new space and planning to hire over 100 new employees.
4) MassBio Testimony: Healthcare Financing Committee Hearing on Drug Cost & Value – MassBio, 1/19/2016
On January 19th, MassBio, at the request of the Joint Committee on Healthcare Financing, testified at the first in a series of informational sessions intended to provide legislators, stakeholders, and the public with a comprehensive understanding of issues of drug cost and value.
5) Video: Experts predict the future of Big Data at #JPM16 – FierceBiotech, 1/19/2016
Storing, analyzing and managing the big data sets that are being created around genomics for drug development has created challenges for the biopharma industry. Some leaders in the field, including Google and the Broad Institute in Cambridge, MA, have been battering down some of these barriers, making it possible to explore the data for clues about new drug development opportunities.
In this post, Laura Hamilton, MassBio’s Manager of Sales, shares highlights from the 2015 JP Morgan Healthcare Conference. For more MassBio, Boston, and biotech updates from Laura, follow her on Twitter @LHamilton822.
Last month I had the privilege of traveling to San Francisco for the premiere investor conference for the global life sciences industry – the JP Morgan Healthcare conference, A coveted invitation to this elite event is hard to come by, but that doesn’t stop thousands of biotech professionals from traveling to San Francisco to pitch, learn, and network. Aside from the JP Morgan conference, the week consists of other events, company sponsored receptions, one-on-one meetings in hotels and coffee shops and random, meaningful encounters just about everywhere. It was surreal to walk through the streets of a city on the opposite coast and see so many familiar faces from the Massachusetts life sciences cluster!
While in San Francisco, I attended the Biotech Showcase run by the EBD Group. This conference is a perfect way to spend your days during JP Morgan. Biotech Showcase attracts companies looking to present and partner. I participated in one-on-one meetings as well as company pitches. Biotech Showcase also features wonderful panel discussions during the daily lunch break. The hotel was filled with entrepreneurs, investors, and business development professionals which allows for chance meetings at every turn. I would highly recommend the Biotech Showcase as an industry-leading event and a reason to be in San Francisco during the JP Morgan week.
By night the city turns into a networking mecca. Companies sponsor parties where they host their clients and prospects. These receptions act as a catalyst for some of the most meaningful business interactions of the week. People talk about their JP Morgan experience and what the industry is like in their corner of the globe, but most importantly these interactions allow people to share intel or contacts where there may be mutual interest. They say timing is everything and the timing of this event couldn’t be better. Attendees returned home with 100+ business cards of contacts to follow-up with and build their pipeline for 2015.
To complement JP Morgan, MassBio hosts a primer event ahead of time and recap event after to highlight the key takeaways. Our panelists shared some great insights: Kush Parmar from 5AM Ventures explained that “innovation is back and people are looking for game-changing science.” We also heard from Brian Gallagher from SR One who explained that the trend at JPM this year was “excessive exuberance and that there were many big deals producing good macro trends.” Gallagher also said “There is a greater appetite for risk and companies are looking to invest in innovation.”
It was wonderful to see so many MassBio members representing our robust biotech community. I hope the energy and enthusiasm from JPM continues well into 2015 to yield positive business outcomes. It’s not too early to start planning for next year, and I hear that some companies already have! We will see you in 10months for the MassBio 2016 JP Morgan Primer!